<h3>Background</h3> The course and evolution of the SLE depends on the affected organ, adherence to treatment and accumulated organ damage, but ethnicity plays a fundamental role, leading to worse results in the non-Caucasian population. Our goal was to describe the demographic, clinical and serological characteristics of a cohort of patients diagnosed with SLE, treated at a private center in the City of Cali, Colombia. <h3>Methods</h3> Descriptive analytical study of a cohort of patients older than 18 years, diagnosed with Systemic Lupus Erythematosus who met the SLICC 2012 classification criteria and who were treated at a Private Center in the City of Cali, Colombia between January 2016, and January 2023. Categorical variables were expressed in percentages and 95% confidence intervals (95% CI). Continuous variables were expressed as means with standard deviations (SD) and medians with interquartile ranges (IQR). <h3>Results</h3> 848 patients were included. The mean age of the patients attended was 48.4 years (SD: 15.34). 92.2% correspond to the female gender. The median follow-up (time between the first and last visit) was 24.9 months (IQR: 10.0–38.28). The ANA titer that we found most frequently was 1/1280 in 21.77% of the cases followed by 1/640 in 18.08% and 1/160 in 17.34%. The anti-DNA was positive in 42.61% of the cases. Regarding antiphospholipid antibodies, the presence of IgG-anticardiolipin (ACL) was positive in 21.37%, IgM-ACL positive in 18.92%, IgG-B2GP (Beta 2 glycoprotein) in 10% and IgM-B2GP in 5.45% of the cases. Lupus anticoagulant was positive in 5.88% of the cases. Regarding disease activity, most patients (53.47%) presented a SLEDAI of 0 (remission), 32.04% a SLEDAI between 1 and 4 (low activity), 12.86% between 5 and 10 (moderate activity) and only 1.63% a SLEDAI greater than 10 (high activity). <h3>Conclusions</h3> The results are similar to the data published in different national and international studies.